The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Deregulated Signaling Pathways in Glioblastoma Multiforme: Molecular Mechanisms and Therapeutic Targets
Open accessAbstract
Glioblastoma multiforme (GBM) is the most malignant and aggressive type of brain tumor with an average life expectancy of less than 15 months. This is mostly due to the highly mutated genome of GBM, which is characterized by the deregulation of many key signaling pathways involving growth, proliferation, survival, and apoptosis. It is critical to explore novel diagnostic and therapeutic strategies that target these pathways to improve the treatment of malignant glioma in the future. This review summarizes the most common and important pathways that are highly mutated or deregulated in GBM and discusses potential therapeutic strategies targeting these pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
The New WHO Classification of Brain Tumours
Kleihues, P., Burger, P. C., & Scheithauer, B. W. (1993) · Brain Pathology · doi:10.1111/j.1750-3639.1993.tb00752.x · Cited by 1,587
Genetic Pathways to Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070011 · Cited by 1,497
Ohgaki, H., & Kleihues, P. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.6.479 · Cited by 1,381
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Epidemiology and etiology of gliomas
Ohgaki, H., & Kleihues, P. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-0991-y · Cited by 1,252
Regulation of Gliogenesis in the Central Nervous System by the JAK-STAT Signaling Pathway
Bonni, A., Sun, Y., Nadal-Vicens, M., Bhatt, A., Frank, D. A., Rozovsky, I., Stahl, N., Yancopoulos, G. D., & Greenberg, M. E. (1997) · Science · doi:10.1126/science.278.5337.477 · Cited by 1,013
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Complexes of Ras⋅GTP with Raf-1 and Mitogen-Activated Protein Kinase Kinase
Moodie, S. A., Willumsen, B. M., Weber, M. J., & Wolfman, A. (1993) · Science · doi:10.1126/science.8503013 · Cited by 968
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899
Structural alterations of the epidermal growth factor receptor gene in human gliomas.
Wong, A. J., Ruppert, J. M., Bigner, S. H., Grzeschik, C. H., Humphrey, P. A., Bigner, D. S., & Vogelstein, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2965 · Cited by 853
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
Huse, J. T., & Holland, E. C. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2818 · Cited by 763
Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00848.x · Cited by 740
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Thomas, S. M., DeMarco, M., D'Arcangelo, G., Halegoua, S., & Brugge, J. S. (1992) · Cell · doi:10.1016/0092-8674(92)90075-n · Cited by 676
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., Hirano, H., Kuratsu, J., et al. (2003) · PubMed · Cited by 663
Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593
The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus
Strong, J. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3351 · Cited by 552
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L. M., Mason, W., Weller, M., Hong, S., Musib, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 525
Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Homologies Between Signal Transducing G Proteins and ras Gene Products
Hurley, J. B., Simon, M. I., Teplow, D. B., Robishaw, J. D., & Gilman, A. G. (1984) · Science · doi:10.1126/science.6436980 · Cited by 482
Graff, J. R., McNulty, A. M., Hanna, K. R., Konicek, B. W., Lynch, R. L., Bailey, S. N., Banks, C., Capen, A., Goode, R., Lewis, J. E., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0071 · Cited by 442
Hideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., Podar, K., Munshi, N. C., Chauhan, D., Richardson, P. G., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3434 · Cited by 422
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., Fink, K., Robins, H. I., De Angelis, L., Raizer, J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 395
Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.21.13.2508 · Cited by 395
Multiple Routes to Astrocytic Differentiation in the CNS
Rajan, P., & McKay, R. D. G. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-10-03620.1998 · Cited by 387
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR
Zhang, H., Bajraszewski, N., Wu, E., Wang, H., Moseman, A. P., Dabora, S. L., Griffin, J. D., & Kwiatkowski, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28984 · Cited by 381
Prados, M. D., Chang, S. M., Butowski, N., DeBoer, R., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J., Rabbitt, J., Page, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9639 · Cited by 378
Rahaman, S. O., Harbor, P. C., Chernova, O., Barnett, G. H., Vogelbaum, M. A., & Haque, S. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206047 · Cited by 377
Porter, K. R., McCarthy, B. J., Freels, S., Kim, Y., & Davis, F. G. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop066 · Cited by 342
Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway
de la Iglesia, N., Konopka, G., Puram, S. V., Chan, J. A., Bachoo, R. M., You, M. J., Levy, D. E., DePinho, R. A., & Bonni, A. (2008) · Genes & Development · doi:10.1101/gad.1606508 · Cited by 336
Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment
Pope, W. B., Kim, H. J., Huo, J., Alger, J., Brown, M. S., Gjertson, D., Sai, V., Young, J. R., Tekchandani, L., Cloughesy, T., et al. (2009) · Radiology · doi:10.1148/radiol.2521081534 · Cited by 318
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K. A., Wen, P. Y., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop015 · Cited by 299
Riemenschneider, M. J., Büschges, R., Wolter, M., REIFENBERGER, J., Boström, J. P., Kraus, J. A., Schlegel, U. S., & Reifenberger, G. (1999) · PubMed · Cited by 297
Forsyth, P., Roldán, G., George, D., Wallace, C., Palmer, C. A., Morris, D., Cairncross, G., Matthews, M. V., Markert, J., Gillespie, Y., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300403 · Cited by 278
O'Reilly, S. M., Newlands, E. S., Brampton, M., Glaser, M. G., Rice-Edwards, J. M., Illingworth, R. D., Richards, P. G., Kennard, C., Colquhoun, I. R., Lewis, P., et al. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80198-4 · Cited by 277
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Pope, W. B., Lai, A., Nghiemphu, P., Mischel, P., & Cloughesy, T. F. (2006) · Neurology · doi:10.1212/01.wnl.0000208958.29600.87 · Cited by 271
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Chamberlain, M. C. (2006) · Neurology · doi:10.1212/01.wnl.0000250628.10420.d8 · Cited by 264
Li, M., Zhang, Y., Liu, Z., Bharadwaj, U., Wang, H., Wang, X., Zhang, S., Liuzzi, J. P., Chang, S.-M., Cousins, R. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709307104 · Cited by 249
Self-citationTargeted Molecular Therapy of GBM
Mischel, P. S., & Cloughesy, T. F. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00006.x · Cited by 247
Itahana, K., Mao, H., Jin, A., Itahana, Y., Clegg, H. V., Lindström, M. S., Bhat, K. P., Godfrey, V. L., Evan, G. I., & Zhang, Y. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.09.007 · Cited by 245
Self-citationp14ARF Deletion and Methylation in Genetic Pathways to Glioblastomas
Nakamura, M., Watanabe, T., Klangby, U., Asker, C., Wiman, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00388.x · Cited by 237
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sathornsumetee, S., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Marcello, J., Herndon, J. E., Mathe, A., Hamilton, M., Rich, J. N., Norfleet, J. A., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq099 · Cited by 231
Los, M., Roodhart, J. M. L., & Voest, E. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-443 · Cited by 229
Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives
Hirschfeld, S., Ho, P. T. C., Smith, M., & Pazdur, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.138 · Cited by 229
Iwamoto, F. M., Lamborn, K. R., Robins, H. I., Mehta, M. P., Chang, S. M., Butowski, N. A., DeAngelis, L. M., Abrey, L. E., Zhang, W.-T., Prados, M. D., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq025 · Cited by 223
The retinoblastoma gene is involved in malignant progression of astrocytomas
Henson, J. W., Schnitker, B. L., Correa, K. M., von Deimling, A., Fassbender, F., Xu, H., Benedict, W. F., Yandell, D. W., & Louis, D. N. (1994) · Annals of Neurology · doi:10.1002/ana.410360505 · Cited by 217
Thiessen, B., Stewart, C., Tsao, M., Kamel-Reid, S., Schaiquevich, P., Mason, W., Easaw, J., Belanger, K., Forsyth, P., McIntosh, L., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1041-6 · Cited by 209
Uhm, J. H., Ballman, K. V., Wu, W., Giannini, C., Krauss, J. C., Buckner, J. C., James, C. D., Scheithauer, B. W., Behrens, R. J., Flynn, P. J., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.070 · Cited by 192
mTOR signaling in glioblastoma: lessons learned from bench to bedside
Akhavan, D., Cloughesy, T. F., & Mischel, P. S. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq052 · Cited by 191
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
Kreisl, T. N., Lassman, A. B., Mischel, P. S., Rosen, N., Scher, H. I., Teruya-Feldstein, J., Shaffer, D., Lis, E., & Abrey, L. E. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9741-z · Cited by 176
Reifenberger, G., Ichimura, K., REIFENBERGER, J., ELKAHLOUN, A. G., Meltzer, P. S., & Collins, V. P. (1996) · PubMed · Cited by 175
Bahuau, M., Vidaud, D., Jenkins, R. B., Bièche, I., Kimmel, D. W., Assouline, B., Smith, J. S., Alderete, B. E., Cayuela, J., Harpey, J. P., et al. (1998) · PubMed · Cited by 163
MGMT hypermethylation: A prognostic foe, a predictive friend
Jacinto, F. V., & Esteller, M. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.03.013 · Cited by 158
Ohgaki, H., Watanabe, K., Tachibana, O., Sato, K., & Kleihues, P. (1996) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199605000-00017 · Cited by 155
Raizer, J. J., Grimm, S. A., Chamberlain, M. C., Nicholas, M. K., Chandler, J. P., Muro, K., Dubner, S., RADEMAKER, A. W., Renfrow, J. J., & Bredel, M. (2010) · Cancer · doi:10.1002/cncr.25462 · Cited by 153
Fulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M. E., Janzer, R. C., Merlo, A., & Van Meir, E. G. (2000) · Oncogene · doi:10.1038/sj.onc.1203700 · Cited by 146
Reardon, D. A., Dresemann, G. P., Taillibert, S., Campone, M., van den Bent, M. J., Clément, P. M., Blomquist, E., Gordower, L., Schultz, H., Raizer, J. J., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605411 · Cited by 141
Non-cell-autonomous action of STAT3 in maintenance of neural precursor cells in the mouse neocortex
Yoshimatsu, T., Kawaguchi, D., Oishi, K., Takeda, K., Akira, S., Masuyama, N., & Gotoh, Y. (2006) · Development · doi:10.1242/dev.02419 · Cited by 140
The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer
Trinh, X. B., Tjalma, W. A. A., Vermeulen, P. B., den Eynden, G. V., der Auwera, I. V., Laere, S. V., Helleman, J., Berns, E., Dirix, L. Y., & van Dam, P. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604921 · Cited by 139
Reardon, D. A., Vredenburgh, J. J., Desjardins, A., Peters, K. B., Gururangan, S., Sampson, J. H., Marcello, J. E., Herndon, J. E., McLendon, R. E., Janney, D., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0217-6 · Cited by 138
A survey of glioblastoma genomic amplifications and deletions
Rao, S. K., Edwards, J. B., Joshi, A. D., Siu, I., & Riggins, G. J. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9959-4 · Cited by 132
Lespagnard, L., Gancberg, D., Rouas, G., Leclercq, G., Somerhausen, N. D. S.-A., Leo, A. D., Piccart, M. J., Verhest, A. P., & Larsimont, D. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990621)84:3<309::aid-ijc19>3.0.co;2-3 · Cited by 113
Zhang, Y., Bharadwaj, U., Logsdon, C. D., Chen, C., Yao, Q. C., & Li, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2405 · Cited by 112
Self-citationGlioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies
Denysenko, T., Gennero, L., Roos, M. A., Melcarne, A., Junemann, C. V., Faccani, G., Morra, I., Cavallo, G. P., Reguzzi, S., Pescarmona, G., et al. (2010) · Cell Biochemistry and Function · doi:10.1002/cbf.1666 · Cited by 111
Razis, E. D., Selviaridis, P., Labropoulos, S., Norris, J. L., Zhu, M. J., Song, D. D., Kalebic, T., Torrens, M. J., Kalogera‐Fountzila, A., Karkavelas, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1867 · Cited by 110
Louis, D. C. S., Woodcock, J. B., Franzoso, G., Blair, P. J., Carlson, L. M., Murillo, M., Wells, M. R., Williams, A. J., Smoot, D. S., Kaushal, S., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.6490 · Cited by 100
Gerstner, E. R., Eichler, A. F., Plotkin, S. R., Drappatz, J., Doyle, C. L., Xu, L., Duda, D. G., Wen, P. Y., Jain, R. K., & Batchelor, T. T. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0390-7 · Cited by 94
St. Louis, D. C., Woodcock, J. B., Fransozo, G., Blair, P. J., Carlson, L. M., Murillo, M., Wells, M. R., Williams, A. J., Smoot, D. S., Kaushal, S., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.6.3237 · Cited by 87
Sarkaria, J. N., Galanis, E., Wu, W., Peller, P. J., Giannini, C., Brown, P. D., Uhm, J. H., McGraw, S. C., Jaeckle, K. A., & Buckner, J. C. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.05.064 · Cited by 85
Tsunetsugu‐Yokota, Y., Morikawa, Y., Isogai, M., Kawana‐Tachikawa, A., Odawara, T., Nakamura, T., Grassi, M. F. R., Autran, B., & Iwamoto, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.19.10250-10259.2003 · Cited by 82
Labuhn, M., Jones, G., Speel, E. M., Maier, D., Zweifel, C., Gratzl, O., Meir, E. G. V., Hegi, M. E., & Merlo, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204197 · Cited by 75
Uncovering Therapeutic Targets FOR Glioblastoma: A Systems Biology Approach
Huang, P. H., Cavenee, W. K., Furnari, F. B., & White, F. M. (2007) · Cell Cycle · doi:10.4161/cc.6.22.4922 · Cited by 72
Expression of p19 INK4d, CDK4, CDK6 in glioblastoma multiforme
Ng, H. (2000) · British Journal of Neurosurgery · doi:10.1080/02688690042870 · Cited by 65
p53 Mutations versus EGF Receptor Expression in Giant Cell Glioblastomas
Peraud, A., Watanabe, K., Plate, K. H., et al. (1997) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199711000-00008 · Cited by 61
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K., Wen, P. Y., et al. (2009) · Neuro-Oncology · doi:10.1093/neuonc/nop017 · Cited by 56
Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors.
Abal, M., Planagumà, J., Gil‐Moreno, A., Monge, M., González, M., Baró, T., García, A. V., Castellví, J., y Cajal, S. R., Xercavins, J., et al. (2006) · PubMed · doi:10.14670/hh-21.197 · Cited by 53
Solomon, D. A., Kim, J.-S., Jean, W. C., & Waldman, T. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2084 · Cited by 45
Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme.
Albert, L., Karsy, M. J., Murali, R., & Jhanwar‐Uniyal, M. (2009) · PubMed · Cited by 45
Zhi, Y.-H., Song, M., Wang, P., Zhang, T., & Yin, Z. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1072 · Cited by 29
How does the immune system attack cancer?
Morse, M. A., Lyerly, H. K., Clay, T. M., Abdel-Wahab, O. I., Chui, S. Y., Garst, J. L., Gollob, J., Grossi, P. M., Kalady, M. F., Mosca, P. J., et al. (2004) · Current Problems in Surgery · doi:10.1016/j.cpsurg.2003.08.001 · Cited by 15
Cited by
Munoz, J. L., Bliss, S. A., Greco, S. J., Ramkissoon, S. H., Ligon, K. L., & Rameshwar, P. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.60 · Cited by 520
Ludwig, K., & Kornblum, H. I. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2379-y · Cited by 418
The Role of Hypoxia in Glioblastoma Invasion
Monteiro, A., Hill, R., Pilkington, G., & Madureira, P. (2017) · Cells · doi:10.3390/cells6040045 · Cited by 321
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Molecular and Genomic Alterations in Glioblastoma Multiforme
Crespo, I., Vital, A. L., Gonzalez-Tablas, M., Patino, M. D. C., Otero, A., Lopes, M. C., de Oliveira, C., Domingues, P., Orfao, A., & Tabernero, M. D. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.02.023 · Cited by 225
Metadata
- Authors
- Mao, H., LeBrun, D. G., Yang, J., Zhu, V. F., & Li, M.
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2012-01
- Volume
- 30
- Issue
- 1
- Pages
- 48-56
- ISSN
- 0735-7907 (ISSN-L)
- 1532-4192
- OpenAlex
- W2122261182
- Cited by
- 266
- References
- 88
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.